ACH · Accendra Health, Inc.

This filing announces a comprehensive, multi-faceted debt restructuring designed to extend maturities, reduce near-term refinancing risk, and improve covenant flexibility. The core transaction involves issuing $326.25M of new 9.00% First Lien Notes due 2032, backed by a binding backstop agreement that ensures funding even if the public offering is undersubscribed—a critical feature given current market volatility. Concurrently, the Company is launching exchange offers for its existing 2029 and 2030 Notes, offering holders a mix of new First and Second Lien Notes at tiered exchange prices, effectively extending debt maturities while increasing secured leverage. The introduction of a $300M new revolving facility replaces the existing one and includes a sophisticated springing maturity clause that accelerates the facility’s due date if other major debt tranches—specifically the Term B-1 Loans or the 2029/2030 Notes—are not refinanced or extended beyond May 2030, creating strong alignment between lenders and noteholders. The consent solicitations to gut the existing note covenants represent a material reduction in creditor protections, signaling management’s intent to gain operational flexibility, likely in anticipation of future strategic initiatives or cost optimization. All these elements are interdependent and subject to customary conditions, including receipt of requisite consents and satisfaction of early settlement date conditions. The hard deadline of June 30, 2026 introduces time pressure, and failure to close could materially impair the Company’s financial condition, as explicitly cautioned in the filing. For investors, this is a high-stakes refinancing event that reshapes the capital structure’s seniority, maturity profile, and covenant landscape, directly impacting credit risk and recovery prospects.